The continual emergence of highly pathogenic novel coronaviruses and their variants has underscored the importance of neutralizing monoclonal antibodies (mAbs) as a pivotal therapeutic approach. In the present study. we report the specific neutralizing antibodies 13H7 and 9G11. which target the N-terminal domain (NTD) and receptor-binding domain (RBD) of the SARS-CoV-2. https://thebrickes.shop/product-category/headboard/